Low-dose methotrexate ups risk for skin cancer, several adverse events
Treatment with low-dose methotrexate (LD-MTX) leads to small-to-moderate increases in risks for skin cancer and gastrointestinal, infectious, pulmonary and haematologic adverse events (AEs), as well as a decrease in renal AEs, a study has shown.
